Exin Therapeutics vs Revvity

Side-by-side comparison of AI visibility scores, market position, and capabilities

Revvity leads in AI visibility (94 vs 24)
Exin Therapeutics logo

Exin Therapeutics

EmergingHealthcare

General

SF AI neurotherapeutics discovery platform for epilepsy/autism/Parkinson's with multimodal neural AI; animal lab + proof-of-concept + 2 patents in 1.5 months; $25M Philippines lab investment competing with Recursion for AI-driven CNS gene therapy.

AI VisibilityBeta
Overall Score
D24
Category Rank
#551 of 1158
AI Consensus
65%
Trend
up
Per Platform
ChatGPT
17
Perplexity
17
Gemini
30

About

Exin Therapeutics is a San Francisco-based AI-powered neurotherapeutics drug discovery company — pioneering genetic therapies that target neural activity to treat epilepsy, autism spectrum disorder symptoms, Parkinson's disease, and other neurological conditions using a multimodal AI platform that predicts therapeutic candidate potential across multiple neural disorders simultaneously. Using neural activity recordings, behavioral assays, and transcriptomics data as inputs, Exin's AI models identify genetic intervention targets and predict therapeutic outcomes before entering animal studies — compressing the target identification timeline that traditional neuroscience drug discovery requires. The company established an animal research facility, obtained proof-of-concept results in mice, and filed two provisional patents within 1.5 months of San Francisco operations, and is investing approximately $25 million to build the Philippines' first neurotherapeutics laboratory.

Full profile
Revvity logo

Revvity

LeaderHealthcare Tech

Life Science Tools & Diagnostics

Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.

AI VisibilityBeta
Overall Score
A94
Category Rank
#1 of 1
AI Consensus
72%
Trend
up
Per Platform
ChatGPT
92
Perplexity
99
Gemini
96

About

Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.

Full profile

AI Visibility Head-to-Head

24
Overall Score
94
#551
Category Rank
#1
65
AI Consensus
72
up
Trend
up
17
ChatGPT
92
17
Perplexity
99
30
Gemini
96
16
Claude
89
21
Grok
88

Key Details

Category
General
Life Science Tools & Diagnostics
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Revvity
Life Science Tools & Diagnostics

Integrations

Only Revvity
Revvity is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.